

CHAPTER 4(D)

Health certificate

For treated blood products, excluding of equidae, for the manufacture of derived products for purposes outside the feed chain for farmed animals, intended for dispatch to ~~or for transit through~~(\*) the European Union

COUNTRY: UNITED STATES

Veterinary certificate to EU

Part I : Details of dispatched consignment	I.1. Consignor Name Address			I.2. Certificate reference No			I.2.a.									
	Tel.			I.3. Central competent authority <b>APHIS-VS</b>												
	I.5. Consignee Name Address			I.6. Person responsible for the load in EU Name Address												
	Postal code Tel.			Postal code Tel.												
	I.7. Country of origin		ISO code		I.8. Region of origin		Code		I.9. Country of destination		ISO code		I.10. Region of destination		Code	
	I.11. Place of origin Name Approval number Address						I.12. Place of destination Name Address Postal code Custom warehouse <input type="checkbox"/> Approval number									
	Name Approval number Address															
	Name Approval number Address															
	I.13. Place of loading						I.14. Date of departure									
	I.15. Means of transport  Aeroplane <input type="checkbox"/> Ship <input type="checkbox"/> Railway wagon <input type="checkbox"/> Road vehicle <input type="checkbox"/> Other <input type="checkbox"/>  Identification  Documentation references						I.16. Entry BIP in EU									
I.18. Description of commodity						I.17.										
						I.19. Commodity code (HS code)										
						I.20. Quantity										
I.21. Temperature of product  Ambient <input type="checkbox"/> Chilled <input type="checkbox"/> Frozen <input type="checkbox"/>						I.22. Number of packages										



	II. Health information	II.a. Certificate reference No	II.b.	
Part II: Certification	I, the undersigned official veterinarian, declare that I have read and understood Regulation (EC) No 1069/2009 of the European Parliament and of the Council <sup>(1a)</sup> , and in particular Article 8(c) and Article 8(d) and Article 10 thereof, and Commission Regulation (EU) No 142/2011 <sup>(1b)</sup> , and in particular Chapter II of Annex XIV thereto, and certify that:			
	II.1.	the blood products described above consist of blood products that satisfy the requirements below;		
	II.2.	they consist exclusively of blood products not intended for human or animal consumption;		
	II.3.	they have been prepared and stored in a plant supervised by the competent authority, exclusively with the following animal by-products:		
		<sup>(2)</sup> either [- blood of slaughtered animals, which is fit for human consumption in accordance with Union legislation, but is not intended for human consumption for commercial reasons;]		
		<sup>(2)</sup> and/or [- blood of slaughtered animals, which is rejected as unfit for human consumption in accordance with Union legislation, but which did not show any signs of diseases communicable to humans or animals, derived from carcasses that have been slaughtered in a slaughterhouse and were considered fit for human consumption following an ante-mortem inspection in accordance with Union legislation;]		
		<sup>(2)</sup> and/or [- blood of slaughtered animals, which did not show any signs of diseases communicable to humans or animals, obtained from animals that have been slaughtered in a slaughterhouse after having been considered fit for human consumption following an ante-mortem inspection in accordance with Union legislation;]		
		<sup>(2)</sup> and/or [- blood and blood products originating from live animals that did not show clinical signs of any disease communicable through these products to humans or animals;]		
		<sup>(2)</sup> and/or [- blood and blood products derived from the production of products intended for human consumption;]		
		<sup>(2)</sup> and/or [- animal by-products which have been derived from animals which have been submitted to illegal treatment as defined in Article 1(2)(d) of Council Directive 96/22/EC <sup>(2a)</sup> or Article 2(b) of Council Directive 96/23/EC <sup>(2b)</sup> ;]		
		<sup>(2)</sup> and/or [- animal by-products containing residues of other substances and environmental contaminants listed in Group B(3) of Annex I to Directive 96/23/EC, if such residues exceed the permitted levels laid down by Union legislation or, in the absence thereof, in national legislation;]		
II.4.	the blood that these products were manufactured from was been collected in slaughterhouses approved in accordance with Union legislation, in slaughterhouses approved and supervised by the competent authority of the country of collection or from live animals in facilities approved and supervised by the competent authority of the country of collection.			
<sup>(2)</sup> II.5.	In the case of blood products derived from Artiodactyla, Perissodactyla and Proboscidea including their crossbreeds, other than Suidae and Tayassuidae, the products have undergone one of the following treatments, guaranteeing the absence of pathogens of foot-and-mouth disease, vesicular stomatitis, rinderpest, peste des petits ruminants, Rift Valley fever and bluetongue:			
	<sup>(2)</sup> either [heat treatment at a temperature of 65 °C for at least three hours, followed by an effectiveness check;]			
	<sup>(2)</sup> and/or [irradiation at 25 kGy by gamma rays, followed by an effectiveness check;]			
	<sup>(2)</sup> and/or [change in pH to pH 5 for two hours, followed by an effectiveness check;]			
	<sup>(2)</sup> and/or [heat treatment of at least 80 °C throughout their substance, followed by an effectiveness check.]]			
<sup>(2)</sup> II.6.	In the case of blood products derived from Suidae, Tayassuidae, poultry and other avian species, the products have undergone one of the following treatments guaranteeing the absence of pathogens of the following diseases: foot-and-mouth disease, vesicular stomatitis, swine vesicular disease, classical swine fever, African swine fever, Newcastle disease and highly pathogenic avian influenza, as appropriate to the species:			
	<sup>(2)</sup> either [heat treatment at a temperature of 65 °C for at least three hours, followed by an effectiveness check;]			
	<sup>(2)</sup> and/or [irradiation at 25 kGy by gamma rays, followed by an effectiveness check;]			
	<sup>(2)</sup> and/or [heat treatment of at least 80 °C for Suidae/Tayassuidae <sup>(2)</sup> and at least 70°C for poultry and other avian species <sup>(2)</sup> throughout the substance of the product, followed by an effectiveness check]].			
<sup>(2)</sup> II.7.	In the case of blood products derived from species other than those listed in point II.5 or II.6, the products have undergone of the following treatment (please specify):.....]			
II.8.	The products were:			
	<sup>(2)</sup> either [packed in new or sterilised bags or bottles,]			
	<sup>(2)</sup> or [transported in bulk in containers or other means of transport that were thoroughly cleaned and disinfected with a disinfectant approved by the competent authority before use;] and			
	the outer packaging or containers bear labels indicating 'NOT FOR HUMAN OR ANIMAL CONSUMPTION';			
II.9.	the products were stored in enclosed storage;			
II.10.	all precautions were taken to avoid the contamination of the products with pathogenic agents after treatment;			
<sup>(2)</sup> II.11.	The treated blood products described above			
	<sup>(2)</sup> either [is derived from other ruminants than bovine, ovine or caprine animals.]]			
	<sup>(2)</sup> or [is derived from bovine, ovine or caprine animals and does not contain and is not derived from:			
	<sup>(2)</sup> either [bovine, ovine and caprine materials other than those derived from animals born, continuously reared and slaughtered in a country or region classified as posing a negligible BSE risk in accordance with Decision 2007/453/EC.]]			
	<sup>(2)</sup> or [(a) specified risk material as defined in point 1 of Annex V to Regulation (EC) No 999/2001 of the European Parliament and of the Council <sup>(2)</sup> ;			

